FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures ...

Researchers at Columbia University have identified a previously unknown population of fibroblasts that may protect lung tumors from immune attack. The work, published in Nature Immunology, illuminates ...

New research shows that senescent cancer-associated fibroblasts in high-grade serous ovarian cancer secrete Tenascin-C, which ...

Colorectal cancer remains one of the world’s most formidable malignancies, ranking as the third most commonly diagnosed cancer and the second leading cause of cancer-related death. Even as s ...

A new study has identified RUNX1 (RUNX family transcription factor 1) as a key driver of a harmful fibroblast state in skin fibrosis. The work shows that these cells adapt to stress, avoid a form of ...

Human skin is constantly rebuilding itself. Every few weeks, the outermost layers shed and are replaced by new cells pushed up from the base. For decades, scientists believed this renewal depended ...

The research group of Prof. Sanjiv Luther at the Department of Immunobiology of the University of Lausanne has discovered that a fibroblast subtype is essential for coordinating certain immune cells ...

Every organ and tissue progressively loses function and integrity as it ages. In fact, researchers have identified "hallmarks ...

FibroBiologics, Inc. announced that IP Australia has issued a Notice of Acceptance for Australian Patent Application No. 2024200985, titled "Cellular Blend for the Regeneration of Chondrocytes or ...